Moffitt Presentations at ASCO 2026

First-line GemCis +/- immunotherapy vs FGFR in ctDNA-detected FGFR2 fusion=positive advanced cholangiocarcinoma: A real-world analysis
Poster 142
Richard Kim, MD

A phase 2, open-label, single-arm study of lirafugratinib in patients with previously treated, unresectable, locally advanced, or metastatic solid tumors (excluding cholangiocarcinoma) with FGFR2 fusion or rearrangement
Poster 228a
Richard Kim, MD

Phase 2/3 trial of pumitamig (PD-L1 x VEGF-A bsAb) plus chemotherapy versus bevacizumab plus chemoptherapy in previously untreated, unresectable, or metastatic colorectal cancer (ROSETTA CRC-203)
Poster 439A
Tiago Biachi, MD, PhD

A phase 2 study of fedratinib in patients with MDS/MPN and chronic neutrophilic leukemia
1:15-1:21 p.m.
E450A
Andrew Kuykendall, MD

Digital prehabilitation and functional performance signals in older adults undergoing hepatobiliary cancer surgery: A pilot study
Poster 22
Mohammed Al-Jumayli, MD

Genetic associations with chemotherapy-induced nausea and vomiting: A genomic-side association study
Poster 33
Martine Extermann, MD, PhD

Microbiome associations with chemotherapy-induced nausea and vomiting: A metagenomic shotgun sequencing study
Poster 93
Martine Extermann, MD, PhD

Using the NCCN distress thermometer to evaluate clincally elevated levels of distress among caregivers of HSCT
Poster 76
Christine Vinci, PhD

Final results of a first-in-human study of MC1R-targeting radiopharmaceutical 225actinium MTI-201 (255Ac-MTI-201) in metastatic uveal melanoma (mUM)
Poster 236
Nikhil Khushalani, MD

Intratumoral dendritic cell (DC1) therapy prior to neoadjuvant chemotherapy in HER2-positive breast cancer (NATASHA trial)
Poster 384
Hyo Han, MD

Developmental Therapeutics - Immunotherapy
8-11 a.m.
Arie Crown Theater
Lilit Karapetyan, MD (Session Moderator)

Hematologic Malignancies - Plasma Dyscrasia
9:45-11:15 a.m.
E450A
Brandon Blue, MD (Session Moderator)

Spatial immune architecture as used to define progression and treatment response in penil squamous cell carcinoma
130
Firas Hatoum MD 

A propensity score-matched analysis comparing first-line regional, systemic and intralesional treatments for melanoma in-transit metastases in a contemporary patient population
240
Caitlyn Balsay-Patel, MD

Novel adaptive versus continuous dosing of encorafenib and binimetinib in combination with nivolumab in advanced BRAF V600E mutant melanoma.
254
Zeynep Eroglu, MD

Health-related quality of life following tumor-infiltrating lymphocytes (TIL) therapy with commercial lifleucel in metastatic melanoma: Real-world longitudinal patient reported outcomes
263
Kimberly Ward, MPH

A phase II trial of olaparib in combination with pembrolizumab in metastatic uveal melanoma
269
Nikhil Khushalani, MD

Outcomes of neoadjuvant immunotherapy (NeoIO) in Merkel cell carcinoma
305
Lacey Mead, DO

Phase 3 ResQ201A of nogapendekin alfa inbakicept (NAI) plus tisleizumab and docetaxel vs. docetaxel monotherapy for advanced or metastatic NSCLC resistant to ICI therapy
455a
Andreas Saltos, MD

Phase 2 sequential treatment of percutaneous hepatic perfusion with melphalan/hepatic delivery system followed by tebentafusp in the treatment of metastatic uveal mealnoma
484b
Jonathan Zager, MD

A phase II study of neoadjuvant ipilimumab-nivolumab-retatlimab (INR) combination immunotherapy in high-risk resectable melanoma
8:12-8:24 a.m.
S100bc
Ahmad Tarhini, MD, PhD

Intratumoral immunotherapy and local immune activation
1:45-2 p.m.
E450A
Brian Czerniecki, MD, PhD

FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
5:36-5:42 p.m.
Hall D1
Guilherme Rabinowits, MD

Making it personal: Targeting tumor neoantigens
3-4:30 p.m.
Hall D2
Hatem Soliman, MD (Session Moderator)

Immunologic determinants in procured melanoma tissue as drivers of durable response in tumor-infiltrating lymphocyte therapy
5:18-5:30 p.m.
E451
Lilit Karapetyan, MD

Cladribine/cyclophosphamide lymphodepletion efficacy and toxicity in CD19 CAR-T therapy for B-ALL
342
Kriti Gera, MD

Updated analysis of overall survival (OS) with imetelstat (IME) in relapsed/refractory (R/R) myelofibrosis (MF) versus real-world (RW) data, and assessment of RW treatment (tx) patterns
366
Andrew Kuykendall, MD

AI-enabled multimodal adjudication of revised IMWG progession after BCMA CAR-T
400
David Kaldas, MD

Echo cancer advisor: A modular AI framework for interpretable, patient-specific oncology support
401
Ariosto Silva, MD

Comparative safety and efficacy of DKRd versus DVRd regimens in multiple myeloma: A systematic review and meta-analysis
453
M. Bakri Hammami, MD

Precision DC: Personalized neoantigen dendritic cell vaccine pilot trial for high-risk triple-negative breast cancer after neoadjuvant therapy
127b
Hatem Soliman, MD

Phase III trial of brain MRI surveillance in stage IV breast cancer
265b
Kamran Ahmed, MD

Preclinical activity in homoharringtonine against melanoma leptomeningeal disease using patient-derived tumor cells
389
Peter Forsyth, MD

Preclinical evaluation of intrathecal TRP1-targeted CAR T cells: Effects on durable antitumor immunity in melanoma leptomeningeal disease
451
Peter Forsyth, MD

Breaking boundaries in myeloproliferative neoplasms and blastic plasmacytoid dendritic cell neoplasms
10:21-10:33 a.m.
S100a
Andrew Kuykendall, MD